Amicus Therapeutics (FOLD)
(Delayed Data from NSDQ)
$11.65 USD
-0.11 (-0.94%)
Updated Aug 26, 2024 04:00 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Price, Consensus and EPS Surprise
FOLD 11.65 -0.11(-0.94%)
Will FOLD be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for FOLD based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for FOLD
Amicus (FOLD) Banks on Galafold, High Dependence a Concern
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
FOLD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
Amicus Therapeutics (FOLD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Other News for FOLD
3 Biotech Names To Target Now
Amicus price target lowered by $1 at JPMorgan, here's why
Amicus Therapeutics: A Compelling Investment In The Rare Disease Biotech Sector
Analysts Offer Insights on Healthcare Companies: Tourmaline Bio (TRML), Amicus (FOLD) and Kura Oncology (KURA)
Amicus Therapeutics, Inc. 2024 Q2 - Results - Earnings Call Presentation